Pre-made Iodine (131I) Apamistamab benchmark antibody (Radiolabelled antibody, anti-PTPRC therapeutic antibody, Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-875
                                      Pre-made Iodine (131I) Apamistamab benchmark antibody (Radiolabelled antibody, anti-PTPRC therapeutic antibody, Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) | 
|---|---|---|---|---|
| GMP-Bios-INN-875-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-875-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-875-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-875-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Iodine (131I) Apamistamab Biosimilar, Radiolabelled Antibody, Anti-Ptprc Antibody: Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 therapeutic antibody | 
| INN Name | Iodine (131I) Apamistamab | 
| Target | PTPRC | 
| Format | Radiolabelled antibody | 
| Derivation | Mus musculus | 
| Species Reactivity | human | 
| CH1 Isotype | IgG1 - kappa | 
| VD LC | IgG1 - kappa | 
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Actinium Pharmaceuticals, Inc. (New York NY USA) | 
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 | 
 
        <
 
                
                 
             
         
         


